Physician profile
Michael J Conrad
NPI 1871542134
$2,579.61
in general payments reported to CMS, 2019-2025
15 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2022: $175 · 2023: $223 · 2024: $400 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,221 · Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,221.39 |
| Food and Beverage | $837.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $1,392.38 | 2025 | Argyle |
| Stryker Corporation | $271.28 | 2019 | |
| Bard Peripheral Vascular, INC. | $193.84 | 2023 | Crosser Iq, Covera |
| Medtronic, INC. | $153.19 | 2024 | Symplicity G3 |
| Aurinia Pharma U.S., INC. | $140.44 | 2022-2023 | Lupkynis |
| Amgen INC. | $124.99 | 2024 | Tavneos |
| Calliditas Therapeutics US INC. | $121.37 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.16 | 2025 | Terlivaz |
| Scpharmaceuticals INC. | $20.21 | 2025 | |
| Vifor Pharma, INC. | $17.32 | 2022 | |
| Ardelyx, INC. | $16.86 | 2024 | Ibsrela |
| Lemaitre Vascular, INC. | $15.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.79 | 2019 | |
| Travere Therapeutics, INC. | $13.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.